About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Enterobacteriaceae ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Careers
Ridinilazole for Clostridium difficile Infection (CDI) –Reductions in Calprotectin and Lactoferrin During Therapy Ridinilazole for Clostridium difficile Infection (CDI) –Reductions in Calprotectin and Lactoferrin During Therapy June 20, 2016 By CKD Digital
Ridinilazole for Clostridium difficile Infection (CDI) –Reductions in Calprotectin and Lactoferrin During Therapy
Ridinilazole for Clostridium difficile Infection (CDI) –Reductions in Calprotectin and Lactoferrin During Therapy June 20, 2016 By CKD Digital